Feed TECH
TE

Bio-Techne TECH NASDAQ · Healthcare · United States

$72.80 -0.05% -$0.04

Summary

55 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 14 USD is left as net profit.
  • It holds more cash than debt: $350.0M against $285.6M.

What to watch

  • The share price is above the Bulios Fair Price.
  • Revenue grew by only 2.2% a year over the last 3 years.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive
Bulios Fair Price
Overvalued Price today $72.8

By our assumptions the business is worth less than its shares cost today.

P/E today 66.5 2.2% lower
5-year average P/E 68.0
P/E today 66.5
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 66.5 USD for 1 USD of yearly profit. Over the last five years it was 68.0 USD on average.

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 5.5% a year over 5 years. Over the last 3 years it grew by 2.2% a year. For the next fiscal year analysts expect revenue to grow by 4.7%.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Biotechnology) -11 USD

Out of every 100 USD of revenue, 14 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

Small, safe
Yield
0.44%
Paid out of profit
29%

You receive $0.32 per share a year. The company covers the payout with ease.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $65.78 is 9.6% below today's price. 46% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2026

By product

By region

Consumables brings in 88% of revenue. Royalty grew fastest, by 5.8% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy